Chromogranin A
Device
Brahms GmbH
Total Payments
$378,788
Transactions
11
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $112,754 | 7 | 0 |
| 2017 | $266,034 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $378,788 | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Chromogranin A as surveillance biomarker in patients with cARcinoids - The CASPAR Pilot study | Brahms GmbH | $253,886 | 0 |
| Procalcitonin Decres over 72 hours and outcom in aptients with severe sepsis or septic shock (MOSES) | Brahms GmbH | $80,836 | 0 |
| Retrospective pilot derivation of Chromogranin A threshold to aid in the assessment of progressive disease | Brahms GmbH | $44,002 | 0 |
| Chromogranin A as surveillance biomarker in patients with cARcinoids - The CASPAR Pilot study | Fisher Scientific Company L.L.C. | $64.76 | 0 |
Top Doctors Receiving Payments for Chromogranin A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $378,788 | 11 |
Ad
Manufacturing Companies
- Brahms GmbH $378,723
- Fisher Scientific Company L.L.C. $64.76
Product Information
- Type Device
- Total Payments $378,788
- Total Doctors 0
- Transactions 11
About Chromogranin A
Chromogranin A is a device associated with $378,788 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Brahms GmbH.
Payment data is available from 2017 to 2018. In 2018, $112,754 was paid across 7 transactions to 0 doctors.
The most common payment nature for Chromogranin A is "Unspecified" ($378,788, 100.0% of total).
Chromogranin A is associated with 4 research studies, including "Chromogranin A as surveillance biomarker in patients with cARcinoids - The CASPAR Pilot study" ($253,886).